DUPIXENT simultaneously improved asthma control while reducing or eliminating steroids1,2
No biomarker requirement (VENTURE, ITT population): Reduced or eliminated OCS dose and reduced severe exacerbation rates and improved lung function (secondary endpoints) at Week 241,2,d-f
a At Week 24 with DUPIXENT 300 mg + SOC (n=103) vs 68% with placebo + SOC (n=107).2
b At Week 24 with DUPIXENT 300 mg + SOC (n=103) vs placebo + SOC (n=107) (0.65 vs 1.60; rate ratio: 0.41 [95% CI: 0.26, 0.63]).1
c At Week 24 with DUPIXENT 300 mg + SOC (n=103) vs 10 mL with placebo + SOC (n=107) (LSM difference: 220 mL [95% CI: 90, 340 mL]).2
- Effects on lung function and on oral steroid and exacerbation reduction were similar irrespective of baseline blood eosinophil levels. Subjects with baseline blood eosinophil levels up to 1500 cells/μL were included1
- 70% significant reduction in OCS dose (median 100%) from
baseline at Week 24 with DUPIXENT 300 mg + SOC (n=103)
(95% CI: 60%, 80%) vs 42% (median 50%) with placebo + SOC (n=107) (primary endpoint)1
d ITT population was unrestricted by minimum baseline EOS or other type 2 biomarkers (eg, FeNO or IgE).2
e The baseline mean OCS dose was 12 mg in the placebo group and 11 mg in the group receiving DUPIXENT.1
f Asthma exacerbation was defined as a temporary increase in OCS dose for at least 3 days.1
DUPIXENT eliminated or reduced OCS dose for up to ~3 years5
of patients from venture eliminated their ocs dose
A gradual increase in the number of patients eliminating their OCS dose was
observed from 53.3% at Week 0 (n=48) to 59.6% at Week 48 (n=34)
to 78.9% at Week 96 (n=15) in the DUPIXENT/DUPIXENT group (secondary endpoint)5
- 88% reduction in OCS dose in the DUPIXENT/DUPIXENT group of patients rolled
over from the VENTURE study at
Week 96 (n=19)5
There are limitations associated with open-label study design, including lack of comparator arm, decreasing sample size, and potential continued involvement of responders and attrition of nonresponders.
Results are descriptive.
OCS reduction was at investigators’ discretion.5